title: Low-dose alpha-interferon treatment of chronic myeloid leukemia.
abstract: We treated 29 patients with chronic-phase and accelerated chronic myeloid leukemia (CML) with alpha-interferon in a dose of 2 mU/m2 given subcutaneously daily for 30 days and then three times per week. Most had received prior treatment. Three patients have had sustained hematologic and karyotypic remissions after a median of 22 months of treatment. Three further patients have had complete hematologic and partial karyotypic remissions. At a median follow-up of 48 months, the median survival has not been reached. This dose of alpha-interferon may induce sustained remissions even in pretreated patients and may prolong survival in CML.
authors.affiliation: Leukemia Research Clinic, University of Colorado Health Sciences Center, Denver 80262.
authors.forename: A
authors.initials: A
authors.lastname: Sanchez
authors.forename: W A
authors.initials: WA
authors.lastname: Robinson
authors.forename: A
authors.initials: A
authors.lastname: Cohn
authors.forename: R
authors.initials: R
authors.lastname: Gonzalez
authors.forename: A
authors.initials: A
authors.lastname: Adlakha
mesh_terms: D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D008297:Male; D008875:Middle Aged
chemical_list: D016898:Interferon-alpha